ClinicalTrials.gg
RecruitingNCT06458712Updated Sep 2, 2026

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

A Phase 1 interventional study of DSB2455 in Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency), sponsored by Duke Street Bio Ltd. Recruiting at 21 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Duke Street Bio Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.

02

Conditions studied

  • Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)

Keywords

  • BRCA1, BRCA2, PALB2, RAD51B, RAD51C, RAD51D, Breast, Ovarian, Prostate (mCRPC), Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets/ Metastases
03

In context

Fanconi Anemia, Complementation Group D1

33 studies on the registry are indexed under Fanconi Anemia, Complementation Group D1; 4 are open to participants now.

This study's planned enrollment of 180 is above the median of 107 across 24 interventional studies indexed under Fanconi Anemia, Complementation Group D1.

Browse Fanconi Anemia, Complementation Group D1 studies →

Lead sponsor

This is the only study on the registry with Duke Street Bio Ltd as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant (or legally acceptable representative, if applicable) provides written for the study.
  • Aged ≥18 years of age on the day of signing the informed consent.
  • confirmed diagnosis of locally advanced and/or breast cancer, prostate cancer (mCRPC), ovarian cancer, or pancreatic ductal adenocarcinoma (PDAC) with confirmed gene alterations/ mutations as defined in the protocol
  • Has received prior cancer treatment as outlined in the protocol
  • Has per v1.1, or non-measurable disease as defined in the protocol.
  • performance status of 0 to 1.
  • >12 weeks.
  • Adequate organ function as defined in the protocol.
  • Willing and able to comply with scheduled visits (including follow-up visits), and protocol procedures.
  • Willing and able to undergo imaging procedures as per protocol.
  • Willing to provide blood samples for correlative research purposes.
  • Able to swallow oral medication as an intact dosage form.
  • Prior intervention with an approved non-selective PARP inhibitor is permitted in Dose Escalation only.
  • Has received prior cancer treatment as outlined in the protocol, dependent on disease type.
  • Known asymptomatic or symptomatic , as confirmed by an MRI brain scan, from a primary tumour and meeting the eligibility for the disease types noted above (Dose Expansion only, specific Cohort).

Exclusion criteria

Exclusion Criteria:

  • Myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) or features suggestive of MDS/AML.
  • Has received a prior PARP1-selective inhibitor.
  • Has received prior systemic anti-cancer therapy including agents or device within 2 or 4 weeks prior to study intervention, dependent on the treatment.
  • Received prior radiotherapy within 2 weeks of the start of study intervention or has a history of radiation pneumonitis.
  • Diagnosis of immunodeficiency or receiving chronic systemic therapy (exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of study drug.
  • Has received a live or within 30 days prior to the first dose of study intervention. Note: administration of killed vaccines are allowed.
  • Has had an allogeneic tissue/solid organ transplant.
  • Has an active disease that has required systemic intervention in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
  • History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  • nausea and vomiting, impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drugs.
  • Undergone major surgery, open or significant traumatic injury ≤28 days prior to starting study intervention.
  • Has an active infection requiring systemic therapy or an uncontrolled concurrent illness.
  • Known history of (HIV) infection. No HIV testing is required unless mandated by the local health authority.
  • Known history of or known active virus (HCV)
  • Cirrhosis of the liver.
  • pulmonary illness.
  • Impaired cardiac function or clinically significant cardiac disease.
  • Participants with a healing, serious or open wound, ulcer, or bone fracture within 28 days prior to first dose of study intervention.
  • History or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participants involvement for the full duration of the study.
  • A who has a positive urine pregnancy test (within 72 hours) prior to starting the study intervention. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
  • Weight loss of >5% in the 8-week period prior to starting study intervention.
  • Known allergy or to any of the formulation components of DSB2455.
  • Has received radiation therapy to the lung that is >30Gy within 6 months of the first dose of study intervention.
  • Other disease-specific criteria as outlined in the protocol.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    DSB2455 Dose Escalation & Expansion

    DSB2455 Dose Escalation \& Expansion

    Drug: DSB2455

Interventions

  • DrugDSB2455

    PARP1 selective inhibitor

06

What researchers measure

Primary outcomes

  1. Number of patients demonstrating dose limiting toxicities and SAEs

    Number of patients demonstrating dose limiting toxicities and SAEs

    Time frame: Through study completion, an average of 1 year

  2. Number of patients exhibiting reduction in tumor size.

    Objective Response Rate (ORR)

    Time frame: Through study completion, an average of 1 year

07

Study locations

21 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Aug 2028, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2024
First posted
Jun 14, 2024
StartActual
Nov 21, 2024
Primary completionEst.
Aug 2028
CompletionEst.
Dec 2028
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06458712
Lead sponsor
Duke Street Bio Ltd
Responsible party
Sponsor
First posted
Jun 14, 2024
Start date
Nov 21, 2024
Primary completion
Aug 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 2, 2026

Study contacts

Duke Street Bio
Contact
clinicaltrials@dukesb.com
+44 (0)203 890 8710

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion